23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › MADRIGAL PHARMACEUTICALS INC. › 2023-2024

MADRIGAL PHARMACEUTICALS INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and MADRIGAL PHARMACEUTICALS INC.’s Form 8-K, filed June 27, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Ballot items
  • 288Asset managers, any item
  • 1,847Fund votes
  • June 25, 2024Meeting date

Results at a glance

Meeting of June 25, 2024: 6 items on MADRIGAL PHARMACEUTICALS INC.’s Form 8-K, filed June 27, 2024: 3 elected · 3 approved.

Dissent

Notable dissent: 1 director (12.6% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore MADRIGAL PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by MADRIGAL PHARMACEUTICALS INC.

These tallies are MADRIGAL PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 27, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

MADRIGAL PHARMACEUTICALS INC. — official shareholder meeting results, meeting held June 25, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Bill Sibold 16,222,905---- 154,8962,188,174 99.1%Elected—
Elect Director: Rebecca Taub, M.D. 16,045,750---- 332,0512,188,174 98%Elected—
Elect Director: Fred B. Craves, Ph.D. 14,311,451---- 2,066,3032,188,221 87%Elected—
2. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 18,444,828110,51710,630 ---- 99.4%Approved—
3. The compensation of the Company's named executive officers as described in the Proxy Statement 15,585,020781,21211,522 --2,188,221 95%Approved—
4. An amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total number of shares of common stock available for issuance by 750,000 and extend its duration by 10 years until April 23, 2035, as described in the Proxy Statement 15,941,045428,5378,219 --2,188,174 97%Approved—

Source: MADRIGAL PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 27, 2024 — read the filing on EDGAR.

How asset managers voted at the MADRIGAL PHARMACEUTICALS INC. 2023-2024 meeting

288 asset managers disclosed a vote on at least one MADRIGAL PHARMACEUTICALS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Bill Sibold

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 16,222,905WITHHELD: 154,896
Details: description as filed, official tally, votes by 81 asset managers

Description as filed by funds: Re-election of Class II directors: Bill Sibold

MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Bill Sibold”): 16,222,905 for, 154,896 withheld, per its Form 8-K filed June 27, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal No. 1 : The Company's stockholders elected each of the three Class II nominees named below to serve on the Company's Board of Directors for a three-year term expiring at the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified.”
Support: 99.1% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 80 asset managers voting on “Re-election of Class II directors: Bill Sibold” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
JANUS INVESTMENT FUND1,772,0210 00For
Vanguard1,675,4300 00For
T. Rowe Price587,6720 00For
BlackRock390,1030 00For
Artisan251,2830 00For
Charles Schwab123,6560 00For
American Century91,2300 00For
Fidelity76,6530 00For
OLD WESTBURY FUNDS INC54,4690 00For
Lord Abbett54,4350 00For
TIAA49,1030 00For
JANUS ASPEN SERIES42,4020 00For
FINANCIAL INVESTORS TRUST00 038,632Withhold
Pacific Life36,8700 00For
Invesco35,3390 00For
Brighthouse35,1640 00For
State Street31,1290 00For
Equitable30,8000 00For
Delaware/Macquarie30,1400 00For
Principal1,7320 027,194Mixed
Jackson National27,9350 00For
AIG/SunAmerica27,1120 00For
Direxion Shares ETF Trust23,0160 00For
Waddell & Reed22,1820 00For
ALGER FUNDS II20,3920 00For

Fund voting reports, all 80 managers: 5,715,165 for, 67,243 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “Re-election of Class II directors: Bill Sibold” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH249,7590 00For

Institutional-manager reports, all 1 managers: 249,759 for.

Elect Director: Fred B. Craves, Ph.D.

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 14,311,451WITHHELD: 2,066,303
Details: description as filed, official tally, votes by 81 asset managers

Description as filed by funds: Re-election of Class II directors: Fred B. Craves, Ph.D.

MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Fred B. Craves, Ph.D.”): 14,311,451 for, 2,066,303 withheld, per its Form 8-K filed June 27, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal No. 1 : The Company's stockholders elected each of the three Class II nominees named below to serve on the Company's Board of Directors for a three-year term expiring at the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified.”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 80 asset managers voting on “Re-election of Class II directors: Fred B. Craves, Ph.D.” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
JANUS INVESTMENT FUND1,772,0210 00For
Vanguard1,596,4410 078,989For
T. Rowe Price587,6720 00For
BlackRock00 0390,103Withhold
Artisan251,2830 00For
Charles Schwab00 0123,656Withhold
American Century91,2300 00For
Fidelity70,3870 06,266Mixed
OLD WESTBURY FUNDS INC54,4690 00For
Lord Abbett54,4350 00For
TIAA00 049,103Withhold
JANUS ASPEN SERIES42,4020 00For
FINANCIAL INVESTORS TRUST00 038,632Withhold
Pacific Life31,8650 05,005Mixed
Invesco00 035,339Withhold
Brighthouse120 035,152Withhold
State Street670 031,062Withhold
Equitable3,0900 027,710Mixed
Delaware/Macquarie00 030,140Withhold
Principal1,7320 027,194Mixed
Jackson National00 027,935Withhold
AIG/SunAmerica27,1120 00For
Direxion Shares ETF Trust23,0160 00For
Waddell & Reed00 022,182Withhold
ALGER FUNDS II00 020,392Withhold

Fund voting reports, all 80 managers: 4,729,985 for, 1,052,423 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “Re-election of Class II directors: Fred B. Craves, Ph.D.” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH249,7590 00For

Institutional-manager reports, all 1 managers: 249,759 for.

Elect Director: Rebecca Taub, M.D.

Official resultFund totals may overlapDIRECTOR ELECTIONSReported outcome: Elected

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 16,045,750WITHHELD: 332,051
Details: description as filed, official tally, votes by 81 asset managers

Description as filed by funds: Re-election of Class II directors: Rebecca Taub, M.D.

MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Rebecca Taub, M.D.”): 16,045,750 for, 332,051 withheld, per its Form 8-K filed June 27, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal No. 1 : The Company's stockholders elected each of the three Class II nominees named below to serve on the Company's Board of Directors for a three-year term expiring at the Company's 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified.”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 80 asset managers voting on “Re-election of Class II directors: Rebecca Taub, M.D.” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
JANUS INVESTMENT FUND1,772,0210 00For
Vanguard1,675,4300 00For
T. Rowe Price587,6720 00For
BlackRock390,1030 00For
Artisan251,2830 00For
Charles Schwab123,6560 00For
American Century91,2300 00For
Fidelity76,6530 00For
OLD WESTBURY FUNDS INC54,4690 00For
Lord Abbett54,4350 00For
TIAA49,1030 00For
JANUS ASPEN SERIES42,4020 00For
FINANCIAL INVESTORS TRUST00 038,632Withhold
Pacific Life36,8700 00For
Invesco35,3390 00For
Brighthouse35,1640 00For
State Street720 031,057Withhold
Equitable30,8000 00For
Delaware/Macquarie30,1400 00For
Principal1,7320 027,194Mixed
Jackson National27,9350 00For
AIG/SunAmerica27,1120 00For
Direxion Shares ETF Trust23,0160 00For
Waddell & Reed22,1820 00For
ALGER FUNDS II20,3920 00For

Fund voting reports, all 80 managers: 5,671,061 for, 111,347 withheld. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “Re-election of Class II directors: Rebecca Taub, M.D.” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH249,7590 00For

Institutional-manager reports, all 1 managers: 249,759 for.

An amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total number of shares of…

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 15,941,045AGAINST: 428,537
Details: description as filed, official tally, votes by 82 asset managers

Description as filed by funds: To approve an amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total number of shares of our common stock available for issuance by 750,000 shares and extend its duration by 10 years until April 23, 2035.

MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“4. An amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total number of shares of common stock available for issuance by 750,000 and extend its duration by 10 years until April 23, 2”): 15,941,045 for, 428,537 against — passed, per its Form 8-K filed June 27, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 4 : The Company's stockholders approved an amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total number of shares of common stock available for issuance by 750,000 and extend its duration by 10 years until April 23, 2035, as described in the Prox…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 81 asset managers voting on “To approve an amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total nu” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
JANUS INVESTMENT FUND1,772,0210 00For
Vanguard1,675,4300 00For
T. Rowe Price587,6720 00For
BlackRock390,1030 00For
Artisan251,2830 00For
Charles Schwab123,6560 00For
American Century091,230 00Against
Fidelity76,6530 00For
OLD WESTBURY FUNDS INC54,4690 00For
Lord Abbett54,4350 00For
TIAA49,1030 00For
JANUS ASPEN SERIES42,4020 00For
FINANCIAL INVESTORS TRUST38,6320 00For
Pacific Life36,8700 00For
Invesco35,3390 00For
Brighthouse35,1640 00For
State Street31,1245 00For
Equitable30,8000 00For
Delaware/Macquarie30,1400 00For
Principal28,9260 00For
Jackson National27,9350 00For
AIG/SunAmerica27,1120 00For
Simplify Exchange Traded Funds23,2940 00For
Direxion Shares ETF Trust23,0160 00For
Waddell & Reed22,1820 00For

Fund voting reports, all 81 managers: 5,704,196 for, 100,622 against, 884 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “To approve an amendment to the Madrigal Pharmaceuticals, Inc. 2015 Amended Stock Plan to increase the total nu” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH249,7590 00For

Institutional-manager reports, all 1 managers: 249,759 for.

The compensation of the Company's named executive officers as described in the Proxy Statement

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 15,585,020AGAINST: 781,212
Details: description as filed, official tally, votes by 288 asset managers

Description as filed by funds: Advisory vote to approve executive compensation.

MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“3. The compensation of the Company's named executive officers as described in the Proxy Statement”): 15,585,020 for, 781,212 against — passed, per its Form 8-K filed June 27, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 : The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers as described in the Proxy Statement.”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 82 asset managers voting on “Advisory vote to approve executive compensation.” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
JANUS INVESTMENT FUND1,772,0210 00For
Vanguard1,596,44178,989 00For
T. Rowe Price587,6720 00For
Artisan517,4730 00For
BlackRock390,1030 00For
Charles Schwab0123,656 00Against
American Century091,230 00Against
Fidelity76,349304 00For
OLD WESTBURY FUNDS INC54,4690 00For
Lord Abbett54,4350 00For
TIAA49,1030 00For
JANUS ASPEN SERIES42,4020 00For
FINANCIAL INVESTORS TRUST38,6320 00For
Pacific Life36,8700 00For
Invesco35,3390 00For
Brighthouse35,1640 00For
State Street31,1227 00For
Equitable30,8000 00For
Delaware/Macquarie30,1400 00For
Principal28,9260 00For
Jackson National27,9350 00For
AIG/SunAmerica27,1120 00For
Simplify Exchange Traded Funds23,2940 00For
Direxion Shares ETF Trust23,0160 00For
Waddell & Reed22,1820 00For

Fund voting reports, all 82 managers: 5,710,941 for, 361,339 against, 884 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 228 asset managers voting on “Advisory vote to approve executive compensation.” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Janus Henderson2,487,1930 00For
BAKER BROS. ADVISORS LP1,969,7980 00For
Avoro Capital Advisors LLC923,1020 00For
T. Rowe Price741,3490 00For
RTW INVESTMENTS, LP536,6220 00For
RA CAPITAL MANAGEMENT, L.P.420,9530 00For
BlackRock363,8901,976 00For
Rock Springs Capital Management LP285,9310 00For
Erste Asset Management GmbH249,7590 00For
State Street224,13028 00For
Bain Capital Life Sciences Investors, LLC196,9950 00For
ARMISTICE CAPITAL, LLC175,8830 00For
TCG Crossover Management, LLC149,2830 00For
Fidelity147,1090 00For
Polar Capital Holdings Plc125,3650 00For
Charles Schwab0123,668 00Against
ArrowMark Colorado Holdings LLC098,806 00Against
American Century094,071 00Against
Ensign Peak Advisors, Inc91,0420 00For
EcoR1 Capital, LLC75,0000 00For
EMERALD MUTUAL FUND ADVISERS TRUST66,3590 00For
Northern Trust63,62910 00For
MACQUARIE INVESTMENT MANAGEMENT BUSINESS TRUST62,2610 00For
LORD, ABBETT & CO. LLC61,4270 00For
FRED ALGER MANAGEMENT, LLC3,91855,738 00Mixed

Institutional-manager reports, all 228 managers: 10,474,984 for, 588,684 against, 16 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the…

Official resultFund totals may overlapAUDIT-RELATEDReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

99.4% Approved · of votes cast

FOR 99.4%
FOR: 18,444,828AGAINST: 110,517

Prior year: 99.9% for (June 15, 2023 meeting) ▼ 0.5 pts

Details: description as filed, official tally, votes by 82 asset managers

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

MADRIGAL PHARMACEUTICALS INC.’s own tally for this item (“2. The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024”): 18,444,828 for, 110,517 against — passed, per its Form 8-K filed June 27, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 : The Company's stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 81 asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public account” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
JANUS INVESTMENT FUND1,772,0210 00For
Vanguard1,675,4300 00For
T. Rowe Price587,6720 00For
BlackRock390,1030 00For
Artisan251,2830 00For
Charles Schwab123,6560 00For
American Century91,2300 00For
Fidelity76,6530 00For
OLD WESTBURY FUNDS INC54,4690 00For
Lord Abbett54,4350 00For
TIAA49,1030 00For
JANUS ASPEN SERIES42,4020 00For
FINANCIAL INVESTORS TRUST38,6320 00For
Pacific Life36,8700 00For
Invesco35,3390 00For
Brighthouse35,1640 00For
State Street31,1245 00For
Equitable30,8000 00For
Delaware/Macquarie30,1400 00For
Principal28,9260 00For
Jackson National27,9350 00For
AIG/SunAmerica27,1120 00For
Simplify Exchange Traded Funds23,2940 00For
Direxion Shares ETF Trust23,0160 00For
Waddell & Reed22,1820 00For

Fund voting reports, all 81 managers: 5,802,154 for, 2,664 against, 884 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1 asset manager voting on “To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public account” at MADRIGAL PHARMACEUTICALS INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Erste Asset Management GmbH249,7590 00For

Institutional-manager reports, all 1 managers: 249,759 for.

Largest MADRIGAL PHARMACEUTICALS INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 19,875,427 shares outstanding at the time of that meeting.

Fund voting reports: top MADRIGAL PHARMACEUTICALS INC. shareholders by shares voted on “Advisory vote to approve executive compensation.”, 2023-2024
#Asset manager % of shares outstanding
1JANUS INVESTMENT FUND 8.92%
2Vanguard 8.43%
3T. Rowe Price 2.96%
4Artisan 2.60%
5BlackRock 1.96%
6Charles Schwab 0.62%
7American Century 0.46%
8Fidelity 0.39%
9OLD WESTBURY FUNDS INC 0.27%
10Lord Abbett 0.27%
Institutional-manager reports: top MADRIGAL PHARMACEUTICALS INC. shareholders by shares voted on “Advisory vote to approve executive compensation.”, 2023-2024
#Asset manager % of shares outstanding
1Janus Henderson 12.51%
2BAKER BROS. ADVISORS LP 9.91%
3Avoro Capital Advisors LLC 4.64%
4T. Rowe Price 3.73%
5RTW INVESTMENTS, LP 2.70%
6RA CAPITAL MANAGEMENT, L.P. 2.12%
7BlackRock 1.84%
8Rock Springs Capital Management LP 1.44%
9Erste Asset Management GmbH 1.26%
10State Street 1.13%

Reported MADRIGAL PHARMACEUTICALS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

MADRIGAL PHARMACEUTICALS INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Entities Affiliated with Janus Henderson Group plc2,902,050 14.60%Proxy statement (DEF 14A), proxy filed April 29, 2024
Entities Affiliated with Avoro Capital Advisors LLC2,143,704 10.79%Proxy statement (DEF 14A), proxy filed April 29, 2024
Entities Affiliated with Baker Bros. Advisors LP2,143,704 10.79%Proxy statement (DEF 14A), proxy filed April 29, 2024
Julian Baker2,143,704 10.79%Proxy statement (DEF 14A), proxy filed April 29, 2024
Paul A. Friedman, M.D.2,057,550 10.35%Proxy statement (DEF 14A), proxy filed April 29, 2024
Rebecca Taub, M.D.2,057,550 10.35%Proxy statement (DEF 14A), proxy filed April 29, 2024
Vanguard Group1,812,054 9.12%Form 13F, quarter ended March 31, 2024
Entities Affiliated with The Vanguard Group1,574,742 7.92%Proxy statement (DEF 14A), proxy filed April 29, 2024
BlackRock1,559,712 7.85%Form 13F, quarter ended March 31, 2024
Entities Affiliated with BlackRock, Inc.1,212,562 6.10%Proxy statement (DEF 14A), proxy filed April 29, 2024

Percentages above are of 19,875,427 shares outstanding, as reported by MADRIGAL PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At MADRIGAL PHARMACEUTICALS INC.'s shareholder meeting held June 25, 2024, in the 2023-2024 proxy season, 288 asset managers reported votes on at least one of its 6 ballot items in their SEC Form N-PX filings, covering 1,847 separate fund positions. On the most widely held item on that ballot — Advisory vote to approve executive compensation. — MADRIGAL PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: MADRIGAL PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 27, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from MADRIGAL PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

MADRIGAL PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “MADRIGAL PHARMACEUTICALS (MDGL) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/madrigal-pharmaceuticals-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.